Tanya B. Dorff, MD, FASCO, shares phase 1 data on ABBV-969, an investigational antibody-drug conjugate being explored for metastatic castration-resistant prostate cancer.
Tanya B. Dorff, MD, FASCO
Advertisement
Articles by Tanya B. Dorff, MD, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
3
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5